RegeneRx completes patient enrollment in phase 2b/3 US dry eye trial
The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. The